List of Envarsus Xr drug patents

Envarsus Xr is owned by Veloxis Pharms Inc.

Envarsus Xr contains Tacrolimus.

Envarsus Xr has a total of 22 drug patents out of which 0 drug patents have expired.

Envarsus Xr was authorised for market use on 10 July, 2015.

Envarsus Xr is available in tablet, extended release;oral dosage forms.

Envarsus Xr can be used as prophylaxis of organ rejection; prophylaxis of organ rejection in de novo transplant patient; prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations, prophylaxis of organ rejection, prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; prophylaxis of organ rejection in de novo transplant patient, prophylaxis of organ rejection in de novo transplant patient, prophylaxis of organ rejection; prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; prophylaxis of organ rejection in de novo transplant patient, prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations, prophylaxis of organ rejection in de novo transplant patient; prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations.

The generics of Envarsus Xr are possible to be released after 30 August, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623410 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US8889185 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US9763920 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US8591946 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US8586084 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US11077096 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US8486993 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US9161907 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US8889186 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US8623411 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US10548880 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US7994214 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US9757362 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US8617599 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(1 year, 6 months from now)

US10864199 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients
May, 2028

(5 years from now)

US11123331 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients
May, 2028

(5 years from now)

US11110081 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients
May, 2028

(5 years from now)

US9549918 VELOXIS PHARMS INC Stabilized tacrolimus composition
May, 2028

(5 years from now)

US10166190 VELOXIS PHARMS INC Stabilized tacrolimus composition
May, 2028

(5 years from now)

US11419823 VELOXIS PHARMS INC Stabilized tacrolimus composition
May, 2028

(5 years from now)

US8664239 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients
Aug, 2028

(5 years from now)

US8685998 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients
Aug, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jul 10, 2022

Drugs and Companies using TACROLIMUS ingredient

Market Authorisation Date: 10 July, 2015

Treatment: Prophylaxis of organ rejection; Prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; Prophylaxis of organ rejection in de novo transplant patient

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ENVARSUS XR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in